Nucleic acid for treating mite allergy

Abstract

[Problem] To provide a nucleic acid expected to be useful for treating mite allergy.[Means to be solved] Provided is a nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleic acid comprises a nucleotide sequence encoding a signal peptide, a nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP, a nucleotide sequence encoding an allergen domain comprising Der p 1, Der p 2, Der p 23, and Der p 7, a nucleotide sequence encoding a transmembrane domain and a nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP in this order.

1 . (canceled) 
     
     
         2 . A nucleic acid encoding a chimeric protein, comprising the following nucleotide sequences in this order:
 a nucleotide sequence encoding a signal peptide;   a nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP;   a nucleotide sequence encoding an allergen domain comprising Der p 1, Der p 2, Der p 23, and Der p 7 in this order;   a nucleotide sequence encoding a transmembrane domain; and   a nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP.   
     
     
         3 . The nucleic acid according to  claim 2 , wherein the signal peptide is a signal peptide of LAMP. 
     
     
         4 . The nucleic acid according to  claim 2 , wherein the transmembrane domain is a transmembrane domain of LAMP. 
     
     
         5 . The nucleic acid according to  claim 2 , wherein the signal peptide consists of amino acid numbers 1 to 27 of SEQ ID NO: 2, the intra-organelle stabilizing domain consists of an amino acid sequence of amino acid numbers 28 to 380 of SEQ ID NO: 2, Der p 1 consists of amino acid numbers 383 to 594 of SEQ ID NO: 2, Der p 2 consists of amino acid numbers 599 to 727 of SEQ ID NO: 2, Der p 23 consists of amino acid numbers 732 to 800 of SEQ ID NO: 2, Der p 7 consists of amino acid numbers 805 to 1002 of SEQ ID NO: 2, the transmembrane domain consists of amino acid numbers 1006 to 1028 of SEQ ID NO: 2, and the endosomal/lysosomal targeting domain consists of amino acid numbers 1037 to 1040 of SEQ ID NO: 2. 
     
     
         6 . A nucleic acid encoding a chimeric protein consisting of an amino acid sequence having at least 90% identity to SEQ ID NO: 2, wherein the chimeric protein encoded by the nucleic acid induces Th1-type immunity to an allergen selected from the group consisting of Der p 1, Der p 2, Der p 23, and Der p 7. 
     
     
         7 . A nucleic acid comprising:
 a) a nucleotide sequence encoding a chimeric protein consisting of SEQ ID NO: 2; or   b) a nucleotide sequence encoding a chimeric protein consisting of an amino acid sequence of SEQ ID NO: 2 in which 1 to 10 amino acids are deleted, substituted, inserted and/or added, wherein the chimeric protein encoded by the nucleic acid induces Th1-type immunity to an allergen selected from the group consisting of Der p 1, Der p 2, Der p 23, and Der p 7.   
     
     
         8 . A nucleic acid comprising:
 a nucleotide sequence encoding a chimeric protein consisting of SEQ ID NO: 2.   
     
     
         9 . An expression vector comprising:
 the nucleic acid according to  claim 2 .   
     
     
         10 . An expression vector comprising:
 the nucleic acid according to  claim 8 .   
     
     
         11 . A host cell transformed with the nucleic acid according to  claim 2 . 
     
     
         12 . A method for producing a nucleic acid, comprising:
 culturing a host cell transformed with the nucleic acid according to  claim 2 .   
     
     
         13 . A pharmaceutical composition comprising:
 the expression vector according to  claim 10  and a pharmaceutically acceptable excipient.   
     
     
         14 . A pharmaceutical composition comprising:
 the expression according to  claim 9  and a pharmaceutically acceptable excipient.   
     
     
         15 . A method for preventing or treating mite allergy, comprising administering to a subject in need thereof the expression vector according to  claim 10 . 
     
     
         16 - 17 . (canceled) 
     
     
         18 . The method of  claim 15 , wherein the subject is a human. 
     
     
         19 . A method for preventing or treating mite allergy, comprising administering to a subject in need thereof the expression vector according to  claim 9 . 
     
     
         20 . The method of  claim 19 , wherein the subject is a human. 
     
     
         21 . A method of inducing a TH1-type immune response in a subject, comprising administering to a subject a nucleic acid according to  claim 2 . 
     
     
         22 . A method of inducing a TH1-type immune response in a subject, comprising administering to a subject a nucleic acid according to  claim 8 .